Etan Orgel1, Richard Sposto, Jemily Malvar, Nita L Seibel, Elena Ladas, Paul S Gaynon, David R Freyer. 1. Etan Orgel, Jonathan Jaques Children's Cancer Center, Miller Children's Hospital, Long Beach; Etan Orgel, Paul S. Gaynon, and David R. Freyer, Keck School of Medicine, University of Southern California; Etan Orgel, Richard Sposto, Jemily Malvar, Paul S. Gaynon, and David R. Freyer, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles; Richard Sposto, University of Southern California, Los Angeles, CA; Nita L. Seibel, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and Elena Ladas, Center for Comprehensive Wellness, Columbia University, New York, NY.
Abstract
PURPOSE: Previous studies regarding the influence of weight on event-free survival (EFS) and treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL) considered only weight at diagnosis. Inasmuch as weight varies substantially over treatment, we hypothesized its impact on EFS is instead determined by cumulative time spent at an extreme weight during therapy and on TRT by weight at the time of toxicity. PATIENTS AND METHODS: In a cohort of 2,008 children treated for high-risk ALL in Children's Oncology Group study CCG-1961, we determined the effect on EFS of cumulative time receiving therapy at an extreme weight (either obese or underweight) between end of induction and start of maintenance therapy. We also evaluated the association between weight category and incidence and patterns of TRT during 13,946 treatment courses. RESULTS: Being obese or underweight at diagnosis and for ≥ 50% of the time between end of induction and start of maintenance therapy resulted in inferior EFS (hazard ratios, 1.43 and 2.30, respectively; global P < .001). Normalization of weight during that period resulted in mitigation of this risk comparable to never being obese or underweight. Obese or underweight status at start of each treatment course was significantly associated with specific patterns of TRT. CONCLUSION: Influence of weight extremes on EFS and TRT is not set at diagnosis as previously reported but is moderated by subsequent weight status during intensive postinduction treatment phases. These observations suggest that weight is a potentially addressable risk factor to improve EFS and morbidity in pediatric ALL.
PURPOSE: Previous studies regarding the influence of weight on event-free survival (EFS) and treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL) considered only weight at diagnosis. Inasmuch as weight varies substantially over treatment, we hypothesized its impact on EFS is instead determined by cumulative time spent at an extreme weight during therapy and on TRT by weight at the time of toxicity. PATIENTS AND METHODS: In a cohort of 2,008 children treated for high-risk ALL in Children's Oncology Group study CCG-1961, we determined the effect on EFS of cumulative time receiving therapy at an extreme weight (either obese or underweight) between end of induction and start of maintenance therapy. We also evaluated the association between weight category and incidence and patterns of TRT during 13,946 treatment courses. RESULTS: Being obese or underweight at diagnosis and for ≥ 50% of the time between end of induction and start of maintenance therapy resulted in inferior EFS (hazard ratios, 1.43 and 2.30, respectively; global P < .001). Normalization of weight during that period resulted in mitigation of this risk comparable to never being obese or underweight. Obese or underweight status at start of each treatment course was significantly associated with specific patterns of TRT. CONCLUSION: Influence of weight extremes on EFS and TRT is not set at diagnosis as previously reported but is moderated by subsequent weight status during intensive postinduction treatment phases. These observations suggest that weight is a potentially addressable risk factor to improve EFS and morbidity in pediatric ALL.
Authors: Zuguo Mei; Laurence M Grummer-Strawn; Angelo Pietrobelli; Ailsa Goulding; Michael I Goran; William H Dietz Journal: Am J Clin Nutr Date: 2002-06 Impact factor: 7.045
Authors: P Zuccaro; S Guandalini; R Pacifici; S Pichini; L Di Martino; M Guiducci; M Giuliano; M T Di Tullio; M Pettoello Mantovani Journal: Ther Drug Monit Date: 1991-01 Impact factor: 3.681
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Smita Bhatia; Harland N Sather; Nyla A Heerema; Michael E Trigg; Paul S Gaynon; Leslie L Robison Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: K A Rickard; C M Detamore; T D Coates; J L Grosfeld; R M Weetman; N M White; A J Provisor; L A Boxer; E S Loghmani; T O Oei; P L Yu; R L Baehner Journal: Cancer Date: 1983-08-15 Impact factor: 6.860
Authors: Inna A Nikonorova; Qiaoqiao Zhu; Christina C Signore; Emily T Mirek; William O Jonsson; Bo Kong; Grace L Guo; William J Belden; Tracy G Anthony Journal: J Biol Chem Date: 2019-08-14 Impact factor: 5.157
Authors: Ditte J A Løhmann; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Minna Koskenvuo; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Marie-Louise Hyre Arpe; Sascha Rørvig; Karin Kok; Christian Mølgaard; Thomas Leth Frandsen Journal: Support Care Cancer Date: 2015-04-17 Impact factor: 3.603
Authors: Kirsten K Ness; Sue C Kaste; Liang Zhu; Ching-Hon Pui; Sima Jeha; Paul C Nathan; Hiroto Inaba; Karen Wasilewski-Masker; Durga Shah; Robert J Wells; Robyn E Karlage; Leslie L Robison; Cheryl L Cox Journal: Leuk Lymphoma Date: 2014-08-20